FG-B310

FG-B310 is an antibody-drug conjugate (ADC) currently under development by FutureGen Biopharmaceutical, specifically designed for the treatment of digestive tract tumors. As an ADC, it consists of a monoclonal antibody conjugated to a cytotoxic payload, intended to selectively target and eliminate malignant cells while sparing healthy tissue. While the specific molecular target of the antibody component has not been publicly disclosed by the company, the drug is part of a specialized pipeline focusing on gastrointestinal and other solid tumors. The therapeutic strategy involves the antibody binding to a tumor-associated antigen, followed by internalization and the release of the cytotoxic agent to induce cell death.